Advanced tools are being deployed by Duke Health and others in the fight against vision loss. STORY HIGHLIGHTS Half of ...

Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP ...

It requires prompt treatment and can be vision-threatening. Neovascular glaucoma develops when new blood vessels form over your iris and the area where fluid usually drains from your eye.

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

Glaucoma is often called the “silent thief of sight” because it can damage vision without warning signs. It harms the optic ...

Bausch + Lomb announced today that an affiliate acquired Elios Vision, developer of a minimally invasive glaucoma surgery ...

Bausch + Lomb Corporation (BLCO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical ...

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced a research partnership with the John A.

added, “I am encouraged that TSCPC remains unaffected by the recent glaucoma LCD. TSCPC is a valuable and versatile laser therapy within the glaucoma treatment paradigm.” ...

“The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by 47% from 2020 to 2040.” 1 Compared to other glaucoma surgery ...